Physician profile
Ashish Mohammad Kabir
NPI 1053727396
$83,088.85
in general payments reported to CMS, 2019-2025
73 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,148 · 2020: $2,883 · 2021: $3,838 · 2022: $3,407 · 2023: $8,435 · 2024: $29K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $13K · Travel and Lodging: $7,923 · Honoraria: $4,000 · Education: $19.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,250.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,600.00 |
| Food and Beverage | $13,021.35 |
| Travel and Lodging | $7,923.37 |
| Honoraria | $4,000.00 |
| Education | $19.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $23,612.48 | 2022-2025 | |
| Ucb, INC. | $23,225.21 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Argenx US, INC. | $10,287.69 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Catalyst Pharmaceuticals, INC. | $5,767.96 | 2021-2025 | Fycompa |
| Livanova USA, INC. | $2,411.61 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Medtronic, INC. | $1,331.80 | 2021-2024 | Percept Pc Brainsense |
| Medtronic USA, INC. | $1,197.15 | 2020 | |
| Boston Scientific Corporation | $1,142.56 | 2019 | |
| Abbvie INC. | $1,039.09 | 2020-2025 | |
| Amneal Pharmaceuticals LLC | $825.47 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Acadia Pharmaceuticals INC | $744.61 | 2019-2025 | Nuplazid |
| Biogen, INC. | $738.71 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Sk Life Science, INC. | $734.62 | 2021-2025 | Xcopri |
| Eisai INC. | $613.32 | 2021-2025 | |
| Mdd US Operations, LLC | $575.80 | 2019-2025 | Gocovri, Gocovri |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Kabir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.